Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	3.78B
Revenue (ttm)	715.22M
Net Income (ttm)	-250.10M
Shares Out	124.39M
EPS (ttm)	-2.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,067,261
Open	29.70
Previous Close	29.47
Day's Range	29.41 - 30.50
52-Week Range	24.34 - 71.90
Beta	0.94
Analysts	Buy
Price Target	46.71 (+53.7%)
Earnings Date	Feb 25, 2025

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 706
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://www.apellis.com

Financial Performance

In 2023, Apellis Pharmaceuticals's revenue was $396.59 million, an increase of 425.83% compared to the previous year's $75.42 million. Losses were -$528.63 million, -18.94% less than in 2022.

Analyst Forecast

According to 18 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $46.71, which is an increase of 53.70% from the latest price.

Price Target

$46.71

(53.70% upside)

Analyst Consensus: Buy